Search | Clinical Trials Finder

Conditions: Ulcerative Colitis, Active Moderate
Interventions: Fecal Microbiota Transplant, Placebo; Biological
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: HIV-1 Infection
Interventions: Islatravir, Ulonivirine, BIC/FTC/TAF, Placebo to ISL, Placebo to Ulonivirine, Placebo to BIC/FTC/TAF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • Ft. Pierce, Florida + 7 more

Conditions: Severe Acute Respiratory Syndrome
Interventions: Otilimab, Placebo 1, Placebo 2, Standard of care; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 1,156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 21
States / cities: Mobile, Alabama • Little Rock, Arkansas • Sacramento, California + 18 more

Conditions: Chronic Kidney Disease, Type 1 Diabetes Mellitus
Interventions: Finerenone, Placebo; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 28
States / cities: Surprise, Arizona • Stanford, California • Vallejo, California + 22 more

Conditions: Covid19
Interventions: EDP1815, Placebo; Drug
Lead sponsor: Evelo Biosciences, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: New Brunswick, New Jersey • Newark, New Jersey • Edinburg, Texas

Conditions: Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia
Interventions: VLX-1005, Placebo; Drug
Lead sponsor: Veralox Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 14
States / cities: Stanford, California • Aurora, Colorado • New Haven, Connecticut + 9 more

Conditions: Postoperative Pain
Interventions: Low Dose SKY0402, High Dose SKY0402, Placebo, Fentanyl via PCA, Bupivacaine via epidural; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 5
States / cities: Pasadena, California • Orlando, Florida • Houston, Texas + 1 more

Conditions: Post-Traumatic Stress Disorder
Interventions: Deep TMS System, Sham Treatment; Device
Lead sponsor: Brainsway; Industry
Eligibility: 22 Years to 68 Years
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 12
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 8 more

Conditions: Cardiovascular Diseases
Interventions: Evacetrapib, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 12,092 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 176
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 173 more

Conditions: Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
Interventions: LY2127399, Placebo every 2 weeks, Placebo every 4 weeks, Standard of Care; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 88
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 85 more

Conditions: Ankle Sprains, Musculoskeletal Injury
Interventions: Transcranial Direct Current Stimulation, Sham Transcranial Direct Current Stimulation, Physical Therapy; Other
Lead sponsor: Keller Army Community Hospital; Federal
Eligibility: 18 Years to 40 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: West Point, New York

Conditions: Indolent Systemic Mastocytosis
Interventions: Avapritinib, Placebo; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 15 more

Conditions: Prostate Cancer Metastatic
Interventions: EMD 525797, Placebo, Standard of Care (SoC); Drug · Other
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 12
States / cities: Pleasant Hill, California • Chicago, Illinois • New Orleans, Louisiana + 9 more

Conditions: Heart Failure
Interventions: Ziltivekimab, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 4,874 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 172
States / cities: Alexander City, Alabama • Fairhope, Alabama • Huntsville, Alabama + 141 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Danirixin, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 3 more

Conditions: Nasal Polyps
Interventions: Fevipiprant 150 mg, Fevipiprant 450 mg, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Irvine, California

Conditions: Spinal Cord Injuries, Skeletal Muscle Atrophy, Metabolic Disease
Interventions: Neuromuscular electrical stimulation; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Efficacy and Safety
Interventions: Proxalutamide (GT0918), Placebo; Drug
Lead sponsor: Suzhou Kintor Pharmaceutical Inc,; Industry
Eligibility: 18 Years and older
Enrollment: 733 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Phoenix, Arizona • Long Beach, California • Sandy Springs, Georgia + 5 more

Conditions: Cleft Palates
Interventions: Unasyn, saline solution; Drug · Other
Lead sponsor: Joseph Losee; Other
Eligibility: 3 Months to 18 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Bilateral Primary Osteoarthritis of Knee
Interventions: Autologous Bone Marrow Aspirate Concentrate, Sterile saline; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 99 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Mepolizumab, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 837 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 20
States / cities: Newport Beach, California • Rochester, Minnesota • Saint Charles, Missouri + 17 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: VAY736, Placebo, Standard of Care (SoC); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 7
States / cities: Birmingham, Alabama • Aurora, Colorado • Miami, Florida + 4 more

Conditions: Low Back Pain, Pregnancy
Interventions: Osteopathic Manipulative Treatment, Placebo Ultrasound; Other
Lead sponsor: University of North Texas Health Science Center; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Head and Neck Neoplasms
Interventions: Pembrolizumab, Placebo, Cisplatin, Accelerated Fractionation (AFX) Radiotherapy, Standard Fractionation (SFX) Radiotherapy; Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 804 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 24
States / cities: Los Angeles, California • San Francisco, California • Santa Rosa, California + 21 more

Search by objective public record fields.

Fecal Microbiota Transplant in the Treatment of Ulcerative Colitis

Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease

A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection

A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia

Dose Finding Posterolateral Thoracotomy Study

A Safety & Efficacy Study With Deep Transcranial Magnetic Stimulation for the Treatment of Post-Traumatic Stress Disorder (PTSD)

A Study of Evacetrapib in High-Risk Vascular Disease

A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

Effectiveness of Transcranial Direct Current Stimulation (tDCS).

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations

Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma

Metabolic Health in Individuals With Spinal Cord Injury (SCI)

Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness

Preventing Complications in Cleft Palate Repair With Antibiotics

Use of Autologous Bone Marrow Aspirate Concentrate in Painful Knee Osteoarthritis

Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients

Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

Osteopathic Manipulative Medicine in Pregnancy: Physiologic and Clinical Effects

Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)